Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização

Detalhes bibliográficos
Autor(a) principal: Taguti, Érika
Data de Publicação: 2014
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Biblioteca Digital de Teses e Dissertações do UNIOESTE
Texto Completo: http://tede.unioeste.br/handle/tede/3503
Resumo: The aims of this research were update systematic reviews available about partial and complete economic studies of linezolid and estimate differential cost between intravenous and oral administration with hypothetical linezolid switch therapy (intravenous to oral or nasogastric tube). A systematic review was conducted using the terms "clinical outcomes", "analysis cost", "economic outcomes" and "pharmacoeconomic studies" and "linezolid" in the databases Cochrane, IPA, Medline and Scopus, associated with manual search. It was also conducted a cost-minimization analysis among hospitalized patients who used oral and/or intravenous linezolid forms between August, 2009 and August, 2013 in a public hospital in southern Brazil. The research was presented in three different papers. For systematic review were found 1352 articles, of which 24 fulfilled inclusion criteria for the systematic review of partial economic studies and 43 for systematic review of complete economic evaluations. In general, linezolid showed better clinical and economic outcomes compared to antimicrobials such as vancomycin, daptomycin, teicoplanin, particularly in cases of pneumonia patients, infections of skin and soft tissues, infections of methicillin-resistant Staphylococcus aureus, for systematic review of partil and complete economic evaluations, due to the possibility switch therapy. In study of cost-minimization were evaluated records of 152 patients, 103 (67.8%) were treated with linezolid exclusively intravenous route and in 33 (31.7%) opportunities could have been the exchange to oral form administration of antimicrobial. The total cost per patient (mean) after changing from intravenous to oral administration was significantly lower than the real cost paid per patient (mean) (p<0.001). The cost savings associated with switching to oral linezolid administration would be US$14,328.32 over four years.
id UNIOESTE-1_63792ef53b8fee9983fc070b8b752ea2
oai_identifier_str oai:tede.unioeste.br:tede/3503
network_acronym_str UNIOESTE-1
network_name_str Biblioteca Digital de Teses e Dissertações do UNIOESTE
repository_id_str
spelling Sanches, Andréia Cristina Conegerohttp://lattes.cnpq.br/9706216109598342Silva, Edson Antonio Alves dahttp://lattes.cnpq.br/0072529471507216Gandra, Rinaldo Ferreirahttp://lattes.cnpq.br/1550489676841150Pontarolo, Robertohttp://lattes.cnpq.br/1779931169656381Melo, Eduardo Borges dehttp://lattes.cnpq.br/0732955060928431http://lattes.cnpq.br/2799126783360313Taguti, Érika2018-03-09T19:11:50Z2014-12-17TAGUTI, Érika. Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização. 2014. 120 f. Dissertação (Mestrado - Programa de Pós-Graduação em Ciências Farmacêuticas) - Universidade Estadual do Oeste do Paraná, Cascavel, 2014.http://tede.unioeste.br/handle/tede/3503The aims of this research were update systematic reviews available about partial and complete economic studies of linezolid and estimate differential cost between intravenous and oral administration with hypothetical linezolid switch therapy (intravenous to oral or nasogastric tube). A systematic review was conducted using the terms "clinical outcomes", "analysis cost", "economic outcomes" and "pharmacoeconomic studies" and "linezolid" in the databases Cochrane, IPA, Medline and Scopus, associated with manual search. It was also conducted a cost-minimization analysis among hospitalized patients who used oral and/or intravenous linezolid forms between August, 2009 and August, 2013 in a public hospital in southern Brazil. The research was presented in three different papers. For systematic review were found 1352 articles, of which 24 fulfilled inclusion criteria for the systematic review of partial economic studies and 43 for systematic review of complete economic evaluations. In general, linezolid showed better clinical and economic outcomes compared to antimicrobials such as vancomycin, daptomycin, teicoplanin, particularly in cases of pneumonia patients, infections of skin and soft tissues, infections of methicillin-resistant Staphylococcus aureus, for systematic review of partil and complete economic evaluations, due to the possibility switch therapy. In study of cost-minimization were evaluated records of 152 patients, 103 (67.8%) were treated with linezolid exclusively intravenous route and in 33 (31.7%) opportunities could have been the exchange to oral form administration of antimicrobial. The total cost per patient (mean) after changing from intravenous to oral administration was significantly lower than the real cost paid per patient (mean) (p<0.001). The cost savings associated with switching to oral linezolid administration would be US$14,328.32 over four years.Os objetivos dessa pesquisa foram atualizar as revisões sistemáticas existentes de estudos econômicos parciais e completos da linezolida e descrever a economia de recursos com a hipotética troca da via de administração do medicamento (endovenosa para oral ou sonda nasoenteral) entre pacientes tratados em um hospital público. Foi conduzida uma revisão sistemática de estudos com os termos “clinical outcomes”, “cost analysis”, “economic outcomes” e “pharmacoeconomic studies” e “linezolid”, nas bases de dados Cochrane, IPA, Medline e Scopus, associado a busca manual. Também foi conduzida uma análise de custo-minimização entre pacientes hospitalizados que utilizaram as formas oral e/ou endovenosa de linezolida entre agosto de 2009 e agosto de 2013 em um hospital público paranaense. As pesquisa foram apresentadas em três diferentes artigos. Para a revisão sistemática foram encontrados 1352 artigos, sendo que 24 preencheram os critérios de inclusão para a revisão sistemática de estudos econômicos parciais e 43 para a revisão sistemática de avaliações econômicas completas. No geral, a linezolida mostrou melhores resultados clínicos e econômicos frente a antimicrobianos como vancomicina, daptomicina, teicoplanina, especialmente nos casos de pacientes com pneumonia, infeções de pele e tecidos moles e infeções por Staphylococcus aureus resistente a meticilina, para estudos econômicos parciais e completos, sendo um dos motivos relacionados à troca da via de administração endovenosa para oral. No estudo de custo-minimização, foram avaliados os prontuários de 152 pacientes, sendo 103 (67,8%) deles foram tratados com linezolida exclusivamente pela via endovenosa e em 33 (31,7%) oportunidades poderia ter ocorrido a troca para a forma oral de administração do antimicrobiano. O custo médio por paciente após a troca hipotética seria significativamente menor do que o valor real gasto (p<0,01) e a economia seria de R$ 32.680,03 em quatro anos.Submitted by Neusa Fagundes (neusa.fagundes@unioeste.br) on 2018-03-09T19:11:49Z No. of bitstreams: 2 Érica_Taguti2014.pdf: 1522601 bytes, checksum: 0c0c5940962174392fdd910bcc90e985 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)Made available in DSpace on 2018-03-09T19:11:50Z (GMT). No. of bitstreams: 2 Érica_Taguti2014.pdf: 1522601 bytes, checksum: 0c0c5940962174392fdd910bcc90e985 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2014-12-17Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESapplication/pdfpor6588633818200016417500Universidade Estadual do Oeste do ParanáCascavelPrograma de Pós-Graduação em Ciências FarmacêuticasUNIOESTEBrasilCentro de Ciências Médicas e Farmacêuticashttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessAntibióticosCusto efetividadeCusto-utilidadeFarmacoeconomiaHospitalAntibioticsCost effectivenessCost-utilityPharmacoeconomicsHospitalFARMACIA::ANALISE E CONTROLE E MEDICAMENTOSAvaliação do uso de linezolida: revisão sistemática e estudo de custo-minimizaçãoAssesment of linezolid use: a systematic review and cost-minimization studyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesis7878055067573953101600600600600-894043971338784926762160250746569323362075167498588264571reponame:Biblioteca Digital de Teses e Dissertações do UNIOESTEinstname:Universidade Estadual do Oeste do Paraná (UNIOESTE)instacron:UNIOESTEORIGINALÉrica_Taguti2014.pdfÉrica_Taguti2014.pdfapplication/pdf1522601http://tede.unioeste.br:8080/tede/bitstream/tede/3503/5/%C3%89rica_Taguti2014.pdf0c0c5940962174392fdd910bcc90e985MD55CC-LICENSElicense_urllicense_urltext/plain; charset=utf-849http://tede.unioeste.br:8080/tede/bitstream/tede/3503/2/license_url4afdbb8c545fd630ea7db775da747b2fMD52license_textlicense_texttext/html; charset=utf-80http://tede.unioeste.br:8080/tede/bitstream/tede/3503/3/license_textd41d8cd98f00b204e9800998ecf8427eMD53license_rdflicense_rdfapplication/rdf+xml; charset=utf-80http://tede.unioeste.br:8080/tede/bitstream/tede/3503/4/license_rdfd41d8cd98f00b204e9800998ecf8427eMD54LICENSElicense.txtlicense.txttext/plain; charset=utf-82165http://tede.unioeste.br:8080/tede/bitstream/tede/3503/1/license.txtbd3efa91386c1718a7f26a329fdcb468MD51tede/35032018-03-09 16:11:50.062oai:tede.unioeste.br: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Biblioteca Digital de Teses e Dissertaçõeshttp://tede.unioeste.br/PUBhttp://tede.unioeste.br/oai/requestbiblioteca.repositorio@unioeste.bropendoar:2018-03-09T19:11:50Biblioteca Digital de Teses e Dissertações do UNIOESTE - Universidade Estadual do Oeste do Paraná (UNIOESTE)false
dc.title.por.fl_str_mv Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização
dc.title.alternative.eng.fl_str_mv Assesment of linezolid use: a systematic review and cost-minimization study
title Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização
spellingShingle Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização
Taguti, Érika
Antibióticos
Custo efetividade
Custo-utilidade
Farmacoeconomia
Hospital
Antibiotics
Cost effectiveness
Cost-utility
Pharmacoeconomics
Hospital
FARMACIA::ANALISE E CONTROLE E MEDICAMENTOS
title_short Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização
title_full Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização
title_fullStr Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização
title_full_unstemmed Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização
title_sort Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização
author Taguti, Érika
author_facet Taguti, Érika
author_role author
dc.contributor.advisor1.fl_str_mv Sanches, Andréia Cristina Conegero
dc.contributor.advisor1Lattes.fl_str_mv http://lattes.cnpq.br/9706216109598342
dc.contributor.advisor-co1.fl_str_mv Silva, Edson Antonio Alves da
dc.contributor.advisor-co1Lattes.fl_str_mv http://lattes.cnpq.br/0072529471507216
dc.contributor.referee1.fl_str_mv Gandra, Rinaldo Ferreira
dc.contributor.referee1Lattes.fl_str_mv http://lattes.cnpq.br/1550489676841150
dc.contributor.referee2.fl_str_mv Pontarolo, Roberto
dc.contributor.referee2Lattes.fl_str_mv http://lattes.cnpq.br/1779931169656381
dc.contributor.referee3.fl_str_mv Melo, Eduardo Borges de
dc.contributor.referee3Lattes.fl_str_mv http://lattes.cnpq.br/0732955060928431
dc.contributor.authorLattes.fl_str_mv http://lattes.cnpq.br/2799126783360313
dc.contributor.author.fl_str_mv Taguti, Érika
contributor_str_mv Sanches, Andréia Cristina Conegero
Silva, Edson Antonio Alves da
Gandra, Rinaldo Ferreira
Pontarolo, Roberto
Melo, Eduardo Borges de
dc.subject.por.fl_str_mv Antibióticos
Custo efetividade
Custo-utilidade
Farmacoeconomia
Hospital
topic Antibióticos
Custo efetividade
Custo-utilidade
Farmacoeconomia
Hospital
Antibiotics
Cost effectiveness
Cost-utility
Pharmacoeconomics
Hospital
FARMACIA::ANALISE E CONTROLE E MEDICAMENTOS
dc.subject.eng.fl_str_mv Antibiotics
Cost effectiveness
Cost-utility
Pharmacoeconomics
Hospital
dc.subject.cnpq.fl_str_mv FARMACIA::ANALISE E CONTROLE E MEDICAMENTOS
description The aims of this research were update systematic reviews available about partial and complete economic studies of linezolid and estimate differential cost between intravenous and oral administration with hypothetical linezolid switch therapy (intravenous to oral or nasogastric tube). A systematic review was conducted using the terms "clinical outcomes", "analysis cost", "economic outcomes" and "pharmacoeconomic studies" and "linezolid" in the databases Cochrane, IPA, Medline and Scopus, associated with manual search. It was also conducted a cost-minimization analysis among hospitalized patients who used oral and/or intravenous linezolid forms between August, 2009 and August, 2013 in a public hospital in southern Brazil. The research was presented in three different papers. For systematic review were found 1352 articles, of which 24 fulfilled inclusion criteria for the systematic review of partial economic studies and 43 for systematic review of complete economic evaluations. In general, linezolid showed better clinical and economic outcomes compared to antimicrobials such as vancomycin, daptomycin, teicoplanin, particularly in cases of pneumonia patients, infections of skin and soft tissues, infections of methicillin-resistant Staphylococcus aureus, for systematic review of partil and complete economic evaluations, due to the possibility switch therapy. In study of cost-minimization were evaluated records of 152 patients, 103 (67.8%) were treated with linezolid exclusively intravenous route and in 33 (31.7%) opportunities could have been the exchange to oral form administration of antimicrobial. The total cost per patient (mean) after changing from intravenous to oral administration was significantly lower than the real cost paid per patient (mean) (p<0.001). The cost savings associated with switching to oral linezolid administration would be US$14,328.32 over four years.
publishDate 2014
dc.date.issued.fl_str_mv 2014-12-17
dc.date.accessioned.fl_str_mv 2018-03-09T19:11:50Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.citation.fl_str_mv TAGUTI, Érika. Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização. 2014. 120 f. Dissertação (Mestrado - Programa de Pós-Graduação em Ciências Farmacêuticas) - Universidade Estadual do Oeste do Paraná, Cascavel, 2014.
dc.identifier.uri.fl_str_mv http://tede.unioeste.br/handle/tede/3503
identifier_str_mv TAGUTI, Érika. Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização. 2014. 120 f. Dissertação (Mestrado - Programa de Pós-Graduação em Ciências Farmacêuticas) - Universidade Estadual do Oeste do Paraná, Cascavel, 2014.
url http://tede.unioeste.br/handle/tede/3503
dc.language.iso.fl_str_mv por
language por
dc.relation.program.fl_str_mv 7878055067573953101
dc.relation.confidence.fl_str_mv 600
600
600
600
dc.relation.department.fl_str_mv -8940439713387849267
dc.relation.cnpq.fl_str_mv 6216025074656932336
dc.relation.sponsorship.fl_str_mv 2075167498588264571
dc.rights.driver.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Estadual do Oeste do Paraná
Cascavel
dc.publisher.program.fl_str_mv Programa de Pós-Graduação em Ciências Farmacêuticas
dc.publisher.initials.fl_str_mv UNIOESTE
dc.publisher.country.fl_str_mv Brasil
dc.publisher.department.fl_str_mv Centro de Ciências Médicas e Farmacêuticas
publisher.none.fl_str_mv Universidade Estadual do Oeste do Paraná
Cascavel
dc.source.none.fl_str_mv reponame:Biblioteca Digital de Teses e Dissertações do UNIOESTE
instname:Universidade Estadual do Oeste do Paraná (UNIOESTE)
instacron:UNIOESTE
instname_str Universidade Estadual do Oeste do Paraná (UNIOESTE)
instacron_str UNIOESTE
institution UNIOESTE
reponame_str Biblioteca Digital de Teses e Dissertações do UNIOESTE
collection Biblioteca Digital de Teses e Dissertações do UNIOESTE
bitstream.url.fl_str_mv http://tede.unioeste.br:8080/tede/bitstream/tede/3503/5/%C3%89rica_Taguti2014.pdf
http://tede.unioeste.br:8080/tede/bitstream/tede/3503/2/license_url
http://tede.unioeste.br:8080/tede/bitstream/tede/3503/3/license_text
http://tede.unioeste.br:8080/tede/bitstream/tede/3503/4/license_rdf
http://tede.unioeste.br:8080/tede/bitstream/tede/3503/1/license.txt
bitstream.checksum.fl_str_mv 0c0c5940962174392fdd910bcc90e985
4afdbb8c545fd630ea7db775da747b2f
d41d8cd98f00b204e9800998ecf8427e
d41d8cd98f00b204e9800998ecf8427e
bd3efa91386c1718a7f26a329fdcb468
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Biblioteca Digital de Teses e Dissertações do UNIOESTE - Universidade Estadual do Oeste do Paraná (UNIOESTE)
repository.mail.fl_str_mv biblioteca.repositorio@unioeste.br
_version_ 1811723393299382272